Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A hellenic cooperative oncology group (HECOG) study
dc.contributor.author | Psyrri, A. | en |
dc.contributor.author | Kalogeras, K. T. | en |
dc.contributor.author | Kronenwett, R. | en |
dc.contributor.author | Wirtz, R. M. | en |
dc.contributor.author | Batistatou, Anna | en |
dc.contributor.author | Bournakis, E. | en |
dc.contributor.author | Timotheadou, E. | en |
dc.contributor.author | Gogas, H. | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Christodoulou, C. | en |
dc.contributor.author | Makatsoris, T. | en |
dc.contributor.author | Linardou, H. | en |
dc.contributor.author | Pectasides, Dimitrios | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Economopoulos, T. | en |
dc.contributor.author | Fountzilas, George | en |
dc.creator | Psyrri, A. | en |
dc.creator | Kalogeras, K. T. | en |
dc.creator | Kronenwett, R. | en |
dc.creator | Wirtz, R. M. | en |
dc.creator | Batistatou, Anna | en |
dc.creator | Bournakis, E. | en |
dc.creator | Timotheadou, E. | en |
dc.creator | Gogas, H. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Christodoulou, C. | en |
dc.creator | Makatsoris, T. | en |
dc.creator | Linardou, H. | en |
dc.creator | Pectasides, Dimitrios | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Economopoulos, T. | en |
dc.creator | Fountzilas, George | en |
dc.date.accessioned | 2018-06-22T09:53:01Z | |
dc.date.available | 2018-06-22T09:53:01Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41617 | |
dc.description.abstract | Background: The ubiquitin-proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression. In the present study, we sought to explore the prognostic and/or predictive significance of UBE2C messenger RNA (mRNA) expression on disease-free survival (DFS) and overall survival (OS) in high-risk operable breast cancer patients. Methods: Five hundred and ninety-five high-risk breast cancer patients were treated in a two-arm trial evaluating postoperative, dose-dense sequential chemotherapy with epirubicin followed by CMF (cyclophosphamide, methotrexate and 5-fluorouracil) with or without paclitaxel (Taxol). RNA was extracted from 313 formalin-fixed primary tumor tissue samples followed by one-step quantitative RT-PCR for assessment of mRNA expression of UBE2C. Results: High UBE2C mRNA expression was associated with poor DFS (Wald's P = 0.003) and OS (Wald's P = 0.005). High tumor grade, as well as high Ki67 protein expression, was more frequent in the high-expression group of UBE2C. Results of the Cox multivariate regression analysis revealed that high UBE2C mRNA expression remained an independent adverse prognostic factor for relapse (P = 0.037) and death (P = 0.05). Conclusions: High UBE2C mRNA expression was found to be of adverse prognostic significance in high-risk breast cancer patients. These findings need to be validated in larger cohorts. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Young adult | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast neoplasms | en |
dc.subject | Cancer patient | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Cancer survival | en |
dc.subject | Neoplasm staging | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Quantitative analysis | en |
dc.subject | Retrospective studies | en |
dc.subject | Retrospective study | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Disease-free survival | en |
dc.subject | Human tissue | en |
dc.subject | Disease free survival | en |
dc.subject | Cancer relapse | en |
dc.subject | Overall survival | en |
dc.subject | Epirubicin | en |
dc.subject | Genetic | en |
dc.subject | Protein expression | en |
dc.subject | High risk patient | en |
dc.subject | Unclassified drug | en |
dc.subject | Breast cancer | en |
dc.subject | Cancer grading | en |
dc.subject | Tissue section | en |
dc.subject | Randomized controlled trials as topic | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Gene expression | en |
dc.subject | Kaplan-meier estimate | en |
dc.subject | Rna | en |
dc.subject | Transcription | en |
dc.subject | Multivariate analysis | en |
dc.subject | Messenger rna | en |
dc.subject | Reverse transcription polymerase chain reaction | en |
dc.subject | Ki 67 antigen | en |
dc.subject | Breast surgery | en |
dc.subject | Proportional hazards models | en |
dc.subject | Prognostic value | en |
dc.subject | Messenger | en |
dc.subject | Rna analysis | en |
dc.subject | Predictive value | en |
dc.subject | Drug dose sequence | en |
dc.subject | Mrna | en |
dc.subject | Protein ube2c | en |
dc.subject | Qrt-pcr | en |
dc.subject | Rna extraction | en |
dc.subject | Tumor burden | en |
dc.subject | Ube2c | en |
dc.subject | Ubiquitin conjugating enzyme | en |
dc.subject | Ubiquitin-conjugating enzymes | en |
dc.title | Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A hellenic cooperative oncology group (HECOG) study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdr527 | |
dc.description.volume | 23 | |
dc.description.issue | 6 | |
dc.description.startingpage | 1422 | |
dc.description.endingpage | 1427 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |